Curated News
By: NewsRamp Editorial Staff
October 07, 2026

Lantern Pharma Gets Taiwan IRB Nod for Phase 2 HARMONIC Trial

Discuss on Substack
Original Source

TLDR

  • Lantern Pharma's LP-300 trial expansion in Taiwan and US positions it to capture a larger share of the EGFR L858R lung cancer market.
  • Lantern Pharma received IRB approvals in Taiwan for Phase 2 HARMONIC trial Part 2, testing LP-300 with carboplatin and pemetrexed in EGFR L858R patients.
  • Lantern Pharma's LP-300 trial offers new hope for lung cancer patients with the EGFR L858R mutation, potentially improving survival and quality of life.
  • Lantern Pharma uses AI to identify patients most likely to benefit from its therapies, potentially speeding up drug development.

Impact - Why it Matters

This news matters because it marks a critical expansion of Lantern Pharma's clinical program into Taiwan, a region with a high incidence of EGFR-mutated lung cancer. By opening Part 2 of the HARMONIC trial, Lantern is accelerating the development of LP-300, a potential therapy for patients with the EGFR exon 21 L858R mutation who have progressed after tyrosine kinase inhibitor treatment—a population with significant unmet need. The preliminary data, though early, suggest a meaningful progression-free survival benefit, and the protocol amendment to allow eight cycles could further enhance efficacy. For investors, this progress demonstrates Lantern's ability to execute on its AI-driven precision oncology strategy and could bring it closer to regulatory submission. For patients, it offers hope for a new treatment option in a difficult-to-treat cancer subtype.

Summary

Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, has received regulatory and Institutional Review Board (IRB) approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC™ trial of LP-300. The lead Taiwan site is now open to accrual and actively screening patients, with Lantern anticipating IRB approval at two additional sites during the fourth quarter. In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying patients with the EGFR exon 21 L858R mutation.

Part 2 will enroll patients with the L858R mutation who have progressed after tyrosine kinase inhibitor treatment. The amended protocol allows LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, an increase from six cycles previously. Preliminary data showed median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. The company noted that these findings are preliminary, exploratory, and based on small patient numbers. To view the full press release, visit https://ibn.fm/CqeDR.

Lantern Pharma leverages its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. Its pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN. This update was distributed by BioMedWire, a specialized communications platform focused on the Biotechnology, Biomedical Sciences, and Life Sciences sectors, which is part of the Dynamic Brand Portfolio @ IBN.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma Gets Taiwan IRB Nod for Phase 2 HARMONIC Trial

Blockchain registration record for this content